As Dr Wang explains, the combination of robust efficacy, manageable toxicity, and longer follow-up—along with pooled data ...
In the discussion, Richard Goldberg, MD, a gastrointestinal oncologist at the WVU Cancer Institute, highlighted a fundamental ...
During a live event, Caitlin Costello, MD, discussed the AQUILA trial and its potential impact on treatment for high-risk smoldering myeloma.
ZUMA-2 cohorts drive brexu-cel’s journey in relapsed/refractory mantle cell lymphoma, from high response rates to dose ...
Sikander Ailawadhi, MD discusses the positive sentiments on subcutaneous isatuximab from European regulators and patient ...
Among 5-year survivors in the tebentafusp arm, 44% received tebentafusp as their only therapy. In contrast, 86% of control ...
As regulators examine the on-body injector used with isatuximab in multiple myeloma, Sikander Ailawadhi, MD, provides ...
To address the limitations of binary pCR classification, Pusztai and colleagues developed the residual cancer burden (RCB) ...
LYT-200 plus HMA at 12 mg/kg delivered 45.5% ORR in 11 R/R HR-MDS patients, including 27.3% CRs, despite 100% prior HMA ...
New in the NCCN guidelines is lurbinectedin [Zepzelca] and atezolizumab [Tecentriq] maintenance. 2 There are other ...
Dr Singh also takes viewers inside the critical—and often underappreciated—role of multidisciplinary collaboration, ...
Rashmi Chugh, MD, discusses the early outcomes of a trial of ozekibart plus chemotherapy in Ewing sarcoma. Rashmi Chugh, MD, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results